logo
Share SHARE
FONT-SIZE Plus   Neg

Celgene Int'l.: CHMP Adopts Positive Opinion For REVLIMID - Quick Facts

Celgene International Sàrl (CELG) said the European Medicines Agency's or EMA: Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion for REVLIMID to treat patients with transfusion-dependent anemia due to low or intermediate-1-risk myelodysplastic syndromes or MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

The CHMP, that reviews applications for all 27 member states in the European Union or EU, as well as Norway and Iceland, has recommended approval for REVLIMID in this indication. The European Commission, which generally follows the recommendation of the CHMP, is believed to make its final decision within two to three months.

MDS is a type of cancer where the production of blood cells and platelets by the bone marrow is disrupted, which can often lead to severe anemia, infections and bleeding.

The CHMP positive opinion was based on the results of MDS-004, a phase III, multi-center, randomized, double-blind, placebo-controlled trial. The largest trial of MDS del(5q) patients conducted to-date, MDS-004 compared the efficacy and safety of once-daily oral treatment with REVLIMID to placebo in 205 patients at 37 participating centers throughout Europe.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cable-cutters have now one more reason to do so as live television streaming will be available on YouTube TV in 14 more markets in the U.S. Facebook Chief Operating Officer Sheryl Sandberg has donated nearly $100 million in Facebook shares to charity. This is her second charitable donation within a year. A document was filed on Thursday with the Security and Exchange Commission, which shows that Sandberg transferred shares to a special fund she uses for charitable donations. Ford Motor Co.'s new CEO Jim Hackett has taken a more cautious approach to the automaker's plans for rolling out autonomous vehicles. Ford is currently undertaking a 100-day review of its operations and Hackett indicated at delays to the company's plans to launch a fully-autonomous vehicle by 2021.
comments powered by Disqus
Follow RTT